- Mechanism targets both integrated virus and cccDNA; expected to begin clinical testing by end of 2024 DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Pioneering epigenome editing company Tune Therapeutics ...

Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection. Subscribe to Technology Networks’ daily ...

DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection ...

Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection. Image Credit: Tune Therapeutics The ...

DURHAM, NC and SEATTLE, WA– Nov 13, 2023 – Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV ...